382

Search

Incuron, LLC

Russian Pharmaceutical Company Incuron, LLC was created in January 2010 by private mutual fund with high-risk (venture) investments «Bioprocess Capital Ventures» (onward «Fund») cooperative with American Public Company «Cleveland Biolabs, Inc.»

Incuron Announce Notice of Allowance from FDA to Commence Clinical Testing with CBL0137.

Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fund and Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced the receipt of a Notice of Allowance from

Incuron, LLC announces start of a phase Ib safety and tolerability trial for curaxin CBL0102 in patients with liver tumors of different etiology in Russia

The study is a multicenter open-label, dose escalation, Phase 1b safety and tolerability study in patients with liver metastases of solid tumor of epithelial origin, or primary advanced hepa

Incuron, LLC Announces Start of US Trial With CBL0137

The primary objective of the study is to determine the maximally tolerated dose and recommend a Phase 2 dose for CBL0137 in these patients. Secondary objectives include describing the dose l

Latest news

Cell Reports Publication Elucidates Role of FACT as Accelerator of Tumor Transformation and Potential Marker and Target of Aggressive Cancers

Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fund and Clevel

Incuron, LLC Announces the Successful Completion of a Phase 1 Study of CBL0102

Incuron, LLC Announces the Successful Completion of a Phase 1 Study of CBL0102 Incuron, a joint sub

Incuron, LLC Announces Start of US Trial With CBL0137

The primary objective of the study is to determine the maximally tolerated dose and recommend a Phas

Incuron Announce Start of Phase 1 Trial for CBL0137

The trial is being conducted at five leading oncology centers in the Russian Federation. The primary

Incuron Announce Start of Phase 1 Trial for CBL0137

The trial is being conducted at five leading oncology centers in the Russian Federation. The primary

Incuron Announce CBL0102 Orphan Drug Status for Hepatocellular Carcinoma

A multi-center Phase I trial of CBL0102 is ongoing in the Russian Federation in patients with liver

Incuron, LLC Announces the Successful Completion of a Phase 1 Study of CBL0102

Incuron, LLC Announces the Successful Completion of a Phase 1 Study of CBL0102 Incuron, a joint sub

With the support of the innovation center Skolkovo

Aboute us

Incuron, LLC is a Russian Federation based joint venture founded in January 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures" (hereinafter "Fund"), and Cleveland BioLabs.

Incuron, LLC is developing an innovative pipeline of drugs to treat oncology and autoimmune disease for the global markets. Incuron's research and development operations include activities in both the Russian Federation and the U.S.

Video

 

You are here:   HomeHome